# BRUIN-MCL-321 (NCT04662255)

> Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

No report yet. It can be ordered.

- Drugs tested: pirtobrutinib
- Indication: previously treated BTK inhibitor naïve mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04662255
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Loxo Oncology, Inc.
- Conditions: Lymphoma, Mantle-Cell
- Interventions: Pirtobrutinib; Ibrutinib; Acalabrutinib; Zanubrutinib
- Enrollment: 500
- Primary outcome: To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)

## Indexed commentary on BRUIN-MCL-321 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 6
- Podcasts: 3
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=bruin-mcl-321-nct04662255

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04662255", "email": "<work email>"}; the inbox owner confirms by the emailed link.